<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>5260</number>
    <updateDate>2022-12-30T11:18:34Z</updateDate>
    <updateDateIncludingText>2022-12-30T11:18:34Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2021-09-14</introducedDate>
    <congress>117</congress>
    <constitutionalAuthorityStatementText>
      <![CDATA[<pre>[Congressional Record Volume 167, Number 158 (Tuesday, September 14, 2021)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. PETERS:H.R. 5260.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 3[Page H4524]</pre>]]>
    </constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsju03</systemCode>
            <name>Courts, Intellectual Property, and the Internet Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2022-11-01T19:56:52Z</date>
              </item>
            </activities>
          </item>
          <item>
            <systemCode>hsju05</systemCode>
            <name>Antitrust, Commercial, and Administrative Law Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2022-11-01T19:56:45Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2021-09-14T15:02:25Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2021-09-15T18:35:36Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2021-09-14T15:02:15Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hswm00</systemCode>
        <name>Ways and Means Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hswm02</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2021-09-14T18:02:18Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2021-09-14T15:02:20Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Freedom from Price Gouging Act</title>
        <congress>117</congress>
        <number>2706</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-04-21</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Star Rating for Biosimilars Act</title>
        <congress>117</congress>
        <number>2855</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-04-27</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Affordable Prescriptions for Patients Through Promoting Competition Act of 2021</title>
        <congress>117</congress>
        <number>2873</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-09-29</actionDate>
          <text>Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 27 - 16.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act</title>
        <congress>117</congress>
        <number>2884</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-09-30</actionDate>
          <text>Ordered to be Reported in the Nature of a Substitute by Voice Vote.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <congress>117</congress>
        <number>2891</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-09-29</actionDate>
          <text>Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Capping Drug Costs for Seniors Act of 2021</title>
        <congress>117</congress>
        <number>4417</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-07-14</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Preserve Access to Affordable Generics and Biosimilars Act</title>
        <congress>117</congress>
        <number>1428</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-12-09</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 180.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Affordable Prescriptions for Patients Act of 2021</title>
        <congress>117</congress>
        <number>1435</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-07-29</actionDate>
          <text>Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Seniors Prescription Drug Relief Act</title>
        <congress>117</congress>
        <number>2327</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-07-13</actionDate>
          <text>Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Reduced Costs and Continued Cures Act of 2021</title>
        <congress>117</congress>
        <number>5237</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-11-01</actionDate>
          <text>Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2022-11-01</actionDate>
        <committees>
          <item>
            <systemCode>hsju03</systemCode>
            <name>Courts, Intellectual Property, and the Internet Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-11-01</actionDate>
        <committees>
          <item>
            <systemCode>hsju05</systemCode>
            <name>Antitrust, Commercial, and Administrative Law Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2021-09-15</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2021-09-14</actionDate>
        <committees>
          <item>
            <systemCode>hswm02</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2021-09-14</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2021-09-14</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hswm00</systemCode>
            <name>Ways and Means Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2021-09-14</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2021-09-14</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2021-09-14</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>P000608</bioguideId>
        <fullName>Rep. Peters, Scott H. [D-CA-52]</fullName>
        <firstName>Scott</firstName>
        <lastName>Peters</lastName>
        <party>D</party>
        <state>CA</state>
        <identifiers>
          <bioguideId>P000608</bioguideId>
        </identifiers>
        <middleName>H.</middleName>
        <district>52</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>S001180</bioguideId>
        <fullName>Rep. Schrader, Kurt [D-OR-5]</fullName>
        <firstName>Kurt</firstName>
        <lastName>Schrader</lastName>
        <party>D</party>
        <state>OR</state>
        <identifiers>
          <bioguideId>S001180</bioguideId>
        </identifiers>
        <district>5</district>
        <sponsorshipDate>2021-09-14</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>R000602</bioguideId>
        <fullName>Rep. Rice, Kathleen M. [D-NY-4]</fullName>
        <firstName>Kathleen</firstName>
        <lastName>Rice</lastName>
        <party>D</party>
        <state>NY</state>
        <identifiers>
          <bioguideId>R000602</bioguideId>
        </identifiers>
        <middleName>M.</middleName>
        <district>4</district>
        <sponsorshipDate>2021-09-14</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M001202</bioguideId>
        <fullName>Rep. Murphy, Stephanie N. [D-FL-7]</fullName>
        <firstName>Stephanie</firstName>
        <lastName>Murphy</lastName>
        <party>D</party>
        <state>FL</state>
        <identifiers>
          <bioguideId>M001202</bioguideId>
        </identifiers>
        <middleName>N.</middleName>
        <district>7</district>
        <sponsorshipDate>2021-09-14</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001110</bioguideId>
        <fullName>Rep. Correa, J. Luis [D-CA-46]</fullName>
        <firstName>J.</firstName>
        <lastName>Correa</lastName>
        <party>D</party>
        <state>CA</state>
        <identifiers>
          <bioguideId>C001110</bioguideId>
        </identifiers>
        <middleName>Luis</middleName>
        <district>46</district>
        <sponsorshipDate>2021-09-14</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>G000583</bioguideId>
        <fullName>Rep. Gottheimer, Josh [D-NJ-5]</fullName>
        <firstName>Josh</firstName>
        <lastName>Gottheimer</lastName>
        <party>D</party>
        <state>NJ</state>
        <identifiers>
          <bioguideId>G000583</bioguideId>
        </identifiers>
        <district>5</district>
        <sponsorshipDate>2021-09-20</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Accounting and auditing</name>
        </item>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Administrative remedies</name>
        </item>
        <item>
          <name>Appropriations</name>
        </item>
        <item>
          <name>Civil actions and liability</name>
        </item>
        <item>
          <name>Competition and antitrust</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Consumer affairs</name>
        </item>
        <item>
          <name>Contracts and agency</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Digestive and metabolic diseases</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug therapy</name>
        </item>
        <item>
          <name>Federal Trade Commission (FTC)</name>
        </item>
        <item>
          <name>Genetics</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Health care costs and insurance</name>
        </item>
        <item>
          <name>Health care coverage and access</name>
        </item>
        <item>
          <name>Health care quality</name>
        </item>
        <item>
          <name>Health programs administration and funding</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Home and outpatient care</name>
        </item>
        <item>
          <name>Inflation and prices</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>Intergovernmental relations</name>
        </item>
        <item>
          <name>Judicial review and appeals</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Marketing and advertising</name>
        </item>
        <item>
          <name>Medicaid</name>
        </item>
        <item>
          <name>Medicare</name>
        </item>
        <item>
          <name>Performance measurement</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Public contracts and procurement</name>
        </item>
        <item>
          <name>State and local government operations</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2021-09-14</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2022-08-23T14:41:55Z</updateDate>
        <text>
          <![CDATA[ <p><b>Reduced Costs and Continued Cures Act</b></p> <p>This bill establishes and alters several programs and requirements relating to the prices of prescription drugs. </p> <p>For example, the bill establishes and alters several requirements under Medicare and Medicaid, including</p> <ul> <li>requiring drug manufacturers to issue rebates to the Centers for Medicare &amp; Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,</li> <li>capping annual out-of-pocket spending under the Medicare prescription drug benefit, and</li> <li>increasing the maximum rebate amount under the Medicaid Drug Rebate Program.</li> </ul> <p>The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including </p> <ul> <li>authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,</li> <li>limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and</li> <li>nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.</li> </ul>]]>
        </text>
      </summary>
    </summaries>
    <title>Reduced Costs and Continued Cures Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Reduced Costs and Continued Cures Act</title>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Reduced Costs and Continued Cures Act</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2021-09-14T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117hr5260ih/xml/BILLS-117hr5260ih.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <date/>
        <formats/>
        <type/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2022-11-01</actionDate>
      <text>Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
